RBC Capital Reiterates Sector Perform on Incyte, Maintains $109 Price Target
RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $109 price target.
Stocks · News reference
FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients 12+ Years; Atebrioz Recommended Dosage 100mg Once Daily
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-third-treatment-fibrodysplasia-ossificans-progressiva
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Incyte To Present Data From Its Inflammation And Autoimmunity Portfolio At The European Academy Of Dermatology And Venereology Conference, September 30-October 3
Oral PresentationsAtopic DermatitisAtopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL)(Session: Free Communication 1: Atopic dermatitis/Eczema. Thursday, October
Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.
8-K filing — Mirum Pharmaceuticals, Inc. (MIRM)
Filed: 2026-09-08 AccNo: 0001759425-26-000047 Size: 143 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target
Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and maintains $137 price target.
TD Cowen Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140
TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $145 to $140.